This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0327U only for Vasistera™ from Natera, Inc. Using cell–free DNA (cfDNA) from a maternal plasma specimen, the test analyzes select DNA sequences on an automated platform and uses an algorithm to calculate the likelihood of fetal aneuploidy, such as trisomy 21 (Down syndrome), trisomy 13 (Edwards syndrome), and trisomy 18 (Patau syndrome). The test is a noninvasive prenatal test (NIPT) available early in pregnancy to evaluate for these conditions.
For clinical responsibility, terminology, tips and additional info
start codify free trial.